Exagen Inc. Forecasted to Earn FY2019 Earnings of ($1.96) Per Share (NYSE:XGN)

Exagen Inc. (NYSE:XGN) – Analysts at Cantor Fitzgerald lowered their FY2019 earnings per share (EPS) estimates for shares of Exagen in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst C. Bijou now anticipates that the company will earn ($1.96) per share for the year, down from their previous estimate of ($1.63). Cantor Fitzgerald has a “Overweight” rating and a $18.00 price target on the stock. Cantor Fitzgerald also issued estimates for Exagen’s FY2020 earnings at ($1.56) EPS.

Several other research firms have also commented on XGN. Cowen initiated coverage on shares of Exagen in a research report on Monday, October 14th. They set an “outperform” rating and a $17.00 price target for the company. William Blair initiated coverage on shares of Exagen in a research report on Monday, October 14th. They set an “outperform” rating for the company.

XGN stock opened at $18.70 on Friday. The firm’s 50-day moving average price is $15.25. Exagen has a one year low of $11.54 and a one year high of $21.05.

Several institutional investors and hedge funds have recently bought and sold shares of XGN. Perkins Capital Management Inc. acquired a new position in shares of Exagen during the third quarter valued at about $1,355,000. Teacher Retirement System of Texas acquired a new position in shares of Exagen during the third quarter valued at about $310,000. Russell Investments Group Ltd. acquired a new position in shares of Exagen during the third quarter valued at about $967,000. Finally, Dean Capital Investments Management LLC acquired a new position in shares of Exagen during the third quarter valued at about $221,000.

In related news, major shareholder Bio-Exagen L.P. H.I.G. acquired 859,897 shares of the business’s stock in a transaction dated Thursday, September 19th. The shares were purchased at an average price of $17.24 per share, for a total transaction of $14,824,624.28.

Exagen Company Profile

Exagen Inc operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia.

Further Reading: Investing in Dividend Stocks

Earnings History and Estimates for Exagen (NYSE:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.